Biomarker composition for diagnosing anaphylaxis against shrimp and use thereof

By identifying MHC1, MHC2, hemocyanin, and hemocyanin L1 as allergens specific to anaphylaxis, the biomarker composition addresses the high false negative rate in existing diagnostic methods, offering an accurate diagnostic solution for anaphylaxis in Koreans by detecting IgE binding to these allergens.

WO2024237623A1PCT designated stage expired Publication Date: 2024-11-21AJOU UNIV IND ACADEMIC COOP FOUND
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/006435
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-05-13
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current diagnostic methods for anaphylaxis caused by shrimp allergens in Koreans have a high false negative rate, highlighting the need for specific biomarkers to accurately diagnose anaphylaxis in this population.

Method used

Identification of MHC1, MHC2, hemocyanin, and hemocyanin L1 as allergens specific to anaphylaxis, along with their epitopes, to develop a biomarker composition that can diagnose anaphylaxis by detecting IgE binding to these allergens in biological samples.

Benefits of technology

The proposed biomarker composition effectively identifies anaphylaxis in Koreans by specifically detecting IgE binding to these allergens, providing a new diagnostic tool with improved accuracy over existing methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006435_21112024_PF_FP_ABST
    Figure KR2024006435_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a biomarker for diagnosing anaphylaxis for shrimps by identifying allergens specific to anaphylaxis among allergens derived from shrimps for Koreans. The present invention provides a composition capable of diagnosing anaphylaxis for shrimps by identifying allergens specific to anaphylaxis of Koreans among allergens derived from shrimps and identifying an epitope which is an epitope to which IgE causing anaphylaxis binds in the allergens.
Need to check novelty before this filing date? Find Prior Art

Description

Biomarker composition for diagnosing anaphylaxis in shrimp and use thereof

[0001] The present invention identifies an allergen specific to anaphylaxis among shrimp-derived allergens targeting Koreans and proposes it as a biomarker for diagnosing anaphylaxis to shrimp.

[0002] An allergy is an immune response to a specific antigen, in which the body exhibits an overreaction to that antigen that differs from the body's normal immune response. The antigen that triggers an allergic reaction is called an allergen, and typical allergens include pollen, drugs, plant fibers, bacteria, viruses, foods, chemicals, and hair. Allergic reactions are categorized as immediate and delayed allergies, and the degree of reactivity can vary depending on whether the antigen reacts with B cells or T cells. Severe allergic reactions that make daily life impossible are classified as allergic diseases.

[0003] Food allergies can manifest in a variety of ways, depending on factors such as age, gender, and race. Most cases of food allergy are diagnosed after consuming the food in question. However, food allergies can manifest in a variety of ways, from mild to life-threatening acute systemic reactions. Therefore, it is important to screen for potentially allergenic foods before consuming them.

[0004] Allergies to seafood, in particular, can manifest as acute, systemic allergic reactions like anaphylaxis. Because there are limited treatment options, avoiding the seafood that triggers the allergy is essential for most patients. Most seafood that triggers allergies are crustaceans, including shrimp, prawns, crab, lobster, and crayfish. Various tests are used to identify the foods that may trigger allergies in each patient.

[0005] Allergic diseases are caused because the body recognizes the allergen, triggers an immune response, and then produces IgE antibodies to remember the allergen. When the allergen that triggered the initial immune response re-enters the body, it binds to the IgE attached to the surface of inflammatory cells, causing the release of various inflammatory mediator chemicals within minutes. These chemicals can cause a severe systemic reaction, including acute respiratory distress, decreased blood pressure, loss of consciousness, and shock symptoms. This is called anaphylaxis. This process occurs within a very short period of time, and symptoms can appear within minutes of re-exposure to even a small amount of the allergen. Therefore, it is important to identify and avoid allergens that cause anaphylaxis before exposure if possible.

[0006] Meanwhile, food allergies have been steadily increasing over the past decade, accounting for approximately 2.5% of allergy patients worldwide. The prevalence of food allergies varies by age and region, ranging from 1% to 10%, and the predominant allergenic foods vary by region. As the prevalence of food allergies increases, the proportion of patients diagnosed with anaphylaxis due to food allergens has reportedly increased by 41% over the past five years.

[0007] In particular, allergens to shrimp, a type of seafood, are being clinically tested, and while the most well-known allergen, F24, is being used to test for shrimp allergies, it has been found to have a high false-negative rate in Koreans. As research has revealed that the diagnostic patterns of shrimp allergens vary by region and race, there is a need to identify new allergens suitable for diagnosing allergic diseases or anaphylaxis in Koreans.

[0008] The purpose of the present invention is to provide a new biomarker capable of diagnosing anaphylaxis to shrimp in Koreans, by identifying an allergen specific to anaphylaxis in Koreans among shrimp-derived allergens, and by identifying an epitope, which is an antigenic determining site to which IgE that induces anaphylaxis binds in the allergen, and thereby providing a composition capable of diagnosing anaphylaxis to shrimp.

[0009] The present invention provides a biomarker composition for diagnosing anaphylaxis in shrimp, which comprises as an active ingredient at least one selected from the group consisting of IgE (immunoglobulin E) that specifically binds to MHC1 (Myosin Heavy Chain Type 1), IgE that specifically binds to MHC2 (Myosin Heavy Chain Type 2), IgE that specifically binds to hemocyanin, and IgE that specifically binds to hemocyanin L1.

[0010] In addition, the present invention provides a composition for diagnosing anaphylaxis in shrimp, which comprises as an active ingredient at least one peptide selected from the group consisting of peptides composed of Myosin Heavy Chain Type 1 (MHC1), Myosin Heavy Chain Type 2 (MHC2), Hemocyanin, Hemocyanin L1, and epitopes thereof.

[0011] In addition, the present invention provides a kit for diagnosing anaphylaxis, comprising at least one peptide selected from the group consisting of peptides composed of Myosin Heavy Chain Type 1 (MHC1), Myosin Heavy Chain Type 2 (MHC2), Hemocyanin, Hemocyanin L1, and epitopes thereof.

[0012] In addition, the present invention provides a method for providing information for diagnosing anaphylaxis in shrimp, comprising a step of detecting IgE (immunoglobulin E) that binds to at least one peptide selected from the group consisting of peptides consisting of MHC1 (Myosin Heavy Chain Type 1), MHC2 (Myosin Heavy Chain Type 2), hemocyanin, hemocyanin L1, and epitopes thereof, in a biological sample isolated from a subject.

[0013] According to the present invention, among shrimp-derived allergens, MHC1 (Myosin Heavy Chain Type 1), MHC2 (Myosin Heavy Chain Type 2), hemocyanin, and hemocyanin L1 are identified as allergens specific to anaphylaxis in Koreans, and IgE (immunoglobulin E) that specifically binds to the allergens is detected only in the serum collected from anaphylaxis patients, so that IgE that binds to the allergens can be provided as a new biomarker capable of diagnosing anaphylaxis to shrimp, and an epitope, which is an antigenic determining site that specifically binds to IgE in the allergen, is identified, and a peptide composed of the allergen and the epitope can be used to diagnose anaphylaxis to shrimp in Koreans. It can be provided as a composition for in vitro diagnostic use.

[0014] Figure 1 is a graph showing the false-negative rate of specific IgE tests for shrimp allergen (F24) in Koreans. Among the 45 patients with anaphylaxis, 12 (26.7%) were found to have false-negative results, and among the 54 patients with acute urticaria (AU), 7 (12.9%) were found to have false-negative results.

[0015] Figure 2 shows the results of IgE immunoblotting using sera from the anaphylaxis group and the acute urticaria (AU) group separated according to the presence or absence of house dust mite (HDM) allergy to raw shrimp extract.

[0016] Figure 3 shows the results of LC-MASS analysis performed to identify allergen components specific to anaphylaxis.

[0017] Figure 4 shows the results of IgG and IgE immunoblotting using sera from the anaphylaxis group and acute urticaria (AU) group separated according to the presence or absence of house dust mite (HDM) allergy, for hemocyanin and hemocyanin L1, which are allergens specific for anaphylaxis, manufactured using a recombinant vector.

[0018] Figure 5 shows the results of IgG and IgE immunoblotting using sera from the anaphylaxis group and acute urticaria (AU) group separated according to the presence or absence of house dust mite (HDM) allergy, against MHC1 (Myosin Heavy Chain Type 1), an allergen specific for anaphylaxis produced using a recombinant vector.

[0019] Figure 6 is a schematic diagram of fragmentation of MHC1 (Myosin Heavy Chain Type 1) and MHC2 (Myosin Heavy Chain Type 2) proteins into N-terminal fragment (N), middle fragment (M), and C-terminal fragment (C).

[0020] Figure 7 shows the results of producing peptides corresponding to the N-terminal fragment (N), middle fragment (M), and C-terminal fragment (C) of MHC1 (Myosin Heavy Chain Type 1) and MHC2 (Myosin Heavy Chain Type 2) proteins using a recombinant vector and confirming the expression of the peptides using a Flag antibody.

[0021] Figure 8 shows the results of IgG and IgE immunoblotting using sera from the anaphylaxis group and acute urticaria (AU) group separated according to the presence or absence of house dust mite (HDM) allergy, for peptides corresponding to the N-terminal fragment (N), middle fragment (M), and C-terminal fragment (C) of the MHC1 (Myosin Heavy Chain Type 1) and MHC2 (Myosin Heavy Chain Type 2) proteins.

[0022] Figure 9 is a schematic diagram showing fragmentation of MHC1 (Myosin Heavy Chain Type 1) and MHC2 (Myosin Heavy Chain Type 2) proteins into M1 fragment, M2 fragment, and M3 fragment.

[0023] Figure 10 shows the results of producing peptides corresponding to the M1 fragment, M2 fragment, and M3 fragment of the MHC1 (Myosin Heavy Chain Type 1) and MHC2 (Myosin Heavy Chain Type 2) proteins using a recombinant vector and confirming the expression of the peptides using a Flag antibody.

[0024] Figure 11 shows the results of IgG and IgE immunoblotting using sera from the anaphylaxis group and the acute urticaria (AU) group separated according to the presence or absence of house dust mite (HDM) allergy, for peptides corresponding to the M1 fragment, M2 fragment, and M3 fragment of the MHC1 (Myosin Heavy Chain Type 1) and MHC2 (Myosin Heavy Chain Type 2) proteins.

[0025] The terms used in this specification have been selected from widely used, current terms, taking into account the functions of the present invention. However, these terms may vary depending on the intentions of those skilled in the art, precedents, the emergence of new technologies, etc. Furthermore, in certain cases, terms may be arbitrarily selected by the applicant, and in such cases, their meanings will be described in detail in the relevant description of the invention. Therefore, the terms used in this invention should not be defined simply as names, but rather based on their inherent meanings and the overall content of the present invention.

[0026] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and shall not be interpreted in an idealized or overly formal sense unless explicitly defined herein.

[0027] Numerical ranges are inclusive of the values ​​defined in the ranges above. Any maximum numerical limitation given throughout this specification includes any lower numerical limitation, as if that lower numerical limitation were explicitly stated. Any minimum numerical limitation given throughout this specification includes any higher numerical limitation, as if that higher numerical limitation were explicitly stated. Any numerical limitation given throughout this specification will include any better numerical range within the broader numerical range, as if that narrower numerical limitation were explicitly stated.

[0028] Hereinafter, the present invention will be described in more detail.

[0029] The present inventors have completed the present invention by identifying an allergen specific for anaphylaxis in Koreans among shrimp-derived allergens in order to provide an allergen specific for anaphylaxis among shrimp-derived allergens as a biomarker for diagnosing anaphylaxis in Koreans, and by identifying an epitope, which is an antigenic determining site to which IgE that induces anaphylaxis binds in the allergen.

[0030] The above allergen may refer to an antigen that causes allergies or an antigen that causes allergic diseases. If antibodies are produced within the body through ingestion or contact with any type of substance containing an allergen, an antigen-antibody reaction may occur if the same substance is ingested or contacted again.

[0031] Among the above shrimp-derived allergens, the allergens specific for anaphylaxis in Koreans may be MHC1 (Myosin Heavy Chain Type 1), MHC2 (Myosin Heavy Chain Type 2), Hemocyanin, and Hemocyanin L1. Anaphylaxis to shrimp can be effectively diagnosed by processing a biological sample of a subject with the above anaphylaxis-specific allergen and then confirming whether IgE specifically binding to the above anaphylaxis-specific allergen is detected within the biological sample.

[0032] The above diagnosis includes determining the susceptibility of an individual to a specific disease or condition, determining whether an individual currently has a specific disease or condition, determining the prognosis of an individual with a specific disease or condition, or therametrics (e.g., monitoring the condition of an individual to provide information on the efficacy of treatment). Diagnosing anaphylaxis to shrimp may mean confirming or predicting whether or not a subject has an allergic disease that exhibits a rapid antigen-antibody immune response throughout the body to shrimp, shrimp extracts, and substances derived from shrimp.

[0033] The above shrimp may be, but is not limited to, a whiteleg shrimp with the scientific name Penaeus vannamei or Litopenaeus vannamei, a brine shrimp with the scientific name Artemia franciscana, a North Sea shrimp with the scientific name Crangon crangon, a white-legged freshwater shrimp with the scientific name Exopalaemon modestus or Palaemon modestus, a sand shrimp with the scientific name Metapenaeus ensis, a northern shrimp with the scientific name Pandalus borealis, a brown shrimp with the scientific name Penaeus aztecus, a shrimp with the scientific name Penaeus indicus, and a black tiger shrimp with the scientific name Penaeus monodon.

[0034] The present invention provides a biomarker composition for diagnosing anaphylaxis in shrimp, which comprises as an active ingredient at least one selected from the group consisting of IgE (immunoglobulin E) that specifically binds to MHC1 (Myosin Heavy Chain Type 1), IgE that specifically binds to MHC2 (Myosin Heavy Chain Type 2), IgE that specifically binds to hemocyanin, and IgE that specifically binds to hemocyanin L1.

[0035] The term "biomarker" used in the present invention refers to a substance that can diagnose a biological sample isolated from a subject with a disease by distinguishing it from a biological sample of a normal control group. It may be an antibody that is present or shows an increased pattern in a biological sample of a subject with a disease compared to a normal control group. The biological sample refers to tissue, blood, plasma, urine, or cells isolated from the subject.

[0036] The above IgE (immunoglobulin E) is a type of antibody known in the relevant field, and is a sensitizing antibody that is produced inside the body by an allergen that causes an allergic disease, is produced by plasma cells, and binds to a receptor on the surface of mast cells or basophils. The IgE can bind to an epitope, which is a specific protein region in the allergen, and can also bind to a peptide composed only of an epitope, which is a protein region in the allergen to which the IgE specifically binds.

[0037] The term "antibody" used in the present invention is a term known in the art and refers to a specific immunoglobulin directed against an antigenic site. The antibody in the present invention refers to an antibody that specifically binds to the marker protein of the present invention, and the antibody can be prepared according to a conventional method in the art. The form of the antibody includes a polyclonal antibody or a monoclonal antibody, and all immunoglobulin antibodies are included. The antibody refers to a complete form having two full-length light chains and two full-length heavy chains. The antibody also includes special antibodies such as humanized antibodies.

[0038] The above anaphylaxis is an antigen-antibody immune response that occurs rapidly in the respiratory, circulatory, digestive, skin, or whole body, caused by IgE produced by an allergen that causes allergic disease.

[0039] In addition, the present invention provides a composition for diagnosing anaphylaxis in shrimp, which comprises as an active ingredient at least one peptide selected from the group consisting of peptides composed of Myosin Heavy Chain Type 1 (MHC1), Myosin Heavy Chain Type 2 (MHC2), Hemocyanin, Hemocyanin L1, and epitopes thereof.

[0040] The term "peptide" used in the present invention has the advantage of high binding affinity to target substances and is resistant to denaturation even during heat and chemical treatments. Furthermore, due to its small molecular size, it can be attached to other proteins to form fusion proteins. Specifically, it can be attached to polymer protein chains, making it suitable for use as a diagnostic kit and drug delivery material.

[0041] The above MHC1 (Myosin Heavy Chain Type 1) may be composed of an amino acid sequence of sequence number 5, the above MHC2 (Myosin Heavy Chain Type 2) may be composed of an amino acid sequence of sequence number 6, the above hemocyanin may be composed of an amino acid sequence of sequence number 7, and the above hemocyanin L1 may be composed of an amino acid sequence of sequence number 8.

[0042] The above epitope may be an epitope of the MHC1 (Myosin Heavy Chain Type 1) or an epitope of the MHC2 (Myosin Heavy Chain Type 2), and the MHC1 (Myosin Heavy Chain Type 1) epitope may be a protein region consisting of the 750th to 1500th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, or a protein region consisting of the 1201st to 1913th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, or a protein region consisting of the 801st to 1042nd amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, or a protein region consisting of the 1043rd to 1549th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, or a protein region consisting of the 1043rd to 1549th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5. It may be a protein region consisting of the 1546th to 1913th amino acid sequence, and the epitope of the MHC2 (Myosin Heavy Chain Type 1) may be a protein region consisting of the 650th to 1400th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, or a protein region consisting of the 1300th to 1909th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, or a protein region consisting of the 701st to 1094th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, or a protein region consisting of the 1095th to 1401st amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, or a protein region consisting of the 1400th to 1909th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6.More preferably, the epitope of the MHC1 (Myosin Heavy Chain Type 1) may be a protein region consisting of the 750th to 1500th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, and the epitope of the MHC2 (Myosin Heavy Chain Type 1) may be a protein region consisting of the 650th to 1400th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6.

[0043] In addition, the present invention provides a kit for diagnosing anaphylaxis, comprising at least one peptide selected from the group consisting of peptides composed of Myosin Heavy Chain Type 1 (MHC1), Myosin Heavy Chain Type 2 (MHC2), Hemocyanin, Hemocyanin L1, and epitopes thereof.

[0044] The above kit can be manufactured as a variety of known kits, and specifically, the kit can be manufactured as an immunoassay kit capable of qualitatively or quantitatively analyzing the reactivity between one or more peptides selected from the group consisting of peptides composed of MHC1 (Myosin Heavy Chain Type 1), MHC2 (Myosin Heavy Chain Type 2), hemocyanin, hemocyanin L1, and epitopes thereof and IgE antibodies present in a blood sample of a subject.

[0045] The kit comprises at least one peptide selected from the group consisting of peptides composed of Myosin Heavy Chain Type 1 (MHC1), Myosin Heavy Chain Type 2 (MHC2), Hemocyanin, Hemocyanin L1, and epitopes thereof, and a secondary antibody that specifically binds to the IgE antibody bound to the peptide, wherein the secondary antibody comprises a secondary antibody conjugate to which a label that develops color by reaction with a substrate is conjugated, and may include a chromogenic substrate solution that reacts with the label, a washing solution, an enzyme reaction stop solution, and the like, and may be manufactured into a plurality of separate packagings or compartments containing reagent components to be used.

[0046] The above peptide may be isolated from nature or may be produced using a recombinant vector.

[0047] The above kit can be used to diagnose anaphylaxis to shrimp in Koreans.

[0048] In addition, the present invention provides a method for providing information for diagnosing anaphylaxis in shrimp, comprising a step of detecting IgE (immunoglobulin E) that binds to at least one peptide selected from the group consisting of peptides consisting of MHC1 (Myosin Heavy Chain Type 1), MHC2 (Myosin Heavy Chain Type 2), hemocyanin, hemocyanin L1, and epitopes thereof, in a biological sample isolated from a subject.

[0049] The above biological sample may be at least one selected from the group consisting of blood, plasma, serum, urine, mucus, saliva, tears, sputum, spinal fluid, lymph, respiratory fluid, intestinal fluid, and amniotic fluid.

[0050] Hereinafter, to aid understanding of the present invention, examples will be given in detail. However, the following examples are intended only to illustrate the scope of the present invention and are not intended to limit its scope. These examples are provided to more fully explain the present invention to those of average skill in the art.

[0051]

[0052] Example 1. Analysis of characteristics of anaphylaxis patients

[0053] To identify shrimp allergens specific for anaphylaxis in Koreans, we selected patients allergic to shrimp and crustaceans. The subjects of the experiment included 126 patients, including 52 diagnosed with anaphylaxis (mean age, 38.8 years) and 74 diagnosed with acute urticaria (AU) (mean age, 37.9 years). The anaphylaxis and acute urticaria groups were further divided into two groups based on the presence or absence of house dust mite (HDM) allergy.

[0054] The serum of each subject was collected to measure the level of total IgE and to analyze the presence or absence of specific IgE to F24, a known shrimp allergen. The presence or absence of specific IgE to F24 was performed using the ImmunoCAP test and ELISA. As a result of comparing the levels of specific IgE in anaphylaxis with those in acute urticaria (AU), as shown in Table 1 below, the results of the ImmunoCAP analysis for specific IgE to shrimp allergen (F24) showed that the anaphylaxis group was 9.14±17.4, while the acute urticaria (AU) group was 2.61±5.30 (P=0.022). The ELISA analysis results showed that the anaphylaxis group was 1.11±1.12, and the acute urticaria (AU) group was 0.71±0.85 (P=0.037). The positive rate of allergy to house dust mite (HDM) was 64% in the anaphylaxis group, and 67.7% in the acute urticaria (AU) group (P=0.696). There was no correlation between shrimp allergy and house dust mite allergy in Koreans. As shown in Figure 1, in Koreans, the false negative rate of specific IgE diagnosis to shrimp allergen (F24) was higher in the anaphylaxis group (26.7%) than in the acute urticaria (AU) group (12.9%).

[0055] Anaphylaxis (n=52) Acute Urticaria (n=74) P ​​value Age (years) 38.8±15.5 37.9±16.3 0.75 1 Sex (male) 46.2 52.7 0.58 7 Disease incidence (adult incidence. %) 90.9 94.6 0.68 3 Family history (positive) 48.1 39.2 0.36 3 HDM sensitization rate (positive) 64 67.7 0.69 6 Total IgE (kU / L) 520.1±646.3 370.8±447.4 0.14 1 sIgE (ImmunoCAP, kU / L) 9.14±17.4 2.61±5.3 0.02 2 sIgE (ELISA, OD value)1.11±1.120.71±0.850.037HDM, house dust mite; sIgE, specific immunoglobulin E

[0056]

[0057] Example 2. Identification of allergens specific for anaphylaxis

[0058] To identify allergen components specific to anaphylaxis, pooled serum was subjected to immunoblotting to confirm the presence of specific allergens (Fig. 2). LC-MASS was performed to identify the allergen components specific to anaphylaxis identified in Fig. 2. As a result of performing LC-MASS with respect to allergen components specific for anaphylaxis, a total of four allergens were selected: MHC1 (Myosin Heavy Chain Type 1) (GenBank: AB758443; Protein id: BAM65721.1), MHC2 (Myosin Heavy Chain Type 2) (GenBank: AB758444; Protein id: BAM65722.1), Hemocyanin (GenBank: KY695246; Protein id: ART94437.1), and Hemocyanin L1 (GeneBank: KF193058; protein id: AHY86471.1) (Fig. 3 and Table 2).

[0059] NCBI BLAST단백질 명칭1BAM65722.1myosin heavy chain type 2 [Litopenaeus vannamei]BAM65721.1myosin heavy chain type 1 [Litopenaeus vannamei]2BAM65720.1myosin heavy chain type 2 [Penaeus monodon]BAM65721.1myosin heavy chain type 1 [Litopenaeus vannamei]3BAK61430.1myosin heavy chain type b [Marsupenaeus japonicus]4BAM65720.1myosin heavy chain type 2 [Penaeus monodon]AHY86475.1hemocyanin subunit L1, partial [Litopenaeus vannamei]CAA57880.1hemocyanin [Litopenaeus vannamei]5BAM65720.1myosin heavy chain type 2 [Penaeus monodon]JAM46622.1Acid-sensitive two pore domain K+ channel dTASK-7, partial [Daphnia magna]6BAM65719.1myosin heavy chain type 1 [Penaeus monodon]BAK61430.1myosin heavy chain type b [Marsupenaeus japonicus]JAN24231.1putative ATP-binding cassette sub-family G member [Daphnia magna]7BAM65721.1myosin heavy chain type 1 [Litopenaeus vannamei]BAM65722.1myosin heavy chain type 2 [Litopenaeus vannamei]BAC66140.1projectin [Procambarus clarkii]CDW30013.1alphaactinin, sarcomericlike [Acyrthosiphon pisum] [Lepeophtheirus salmonis]AKI81624.1hemocyanin V4 [Litopenaeus vannamei]AAL27460.1hemocyanin, partial [Penaeus monodon]8sp|A1KYZ2.1|TPM_PENMORecName: Full-Tropomyosin; AltName: Full-Tropomyosin, fast isoform; Short-Tm-Penm-fast9sp|A1KYZ2.1|TPM_PENMORecName: Full-Tropomyosin; AltName: Full-Tropomyosin, fast isoform; Short-Tm-Penm-fast.

[0060]

[0061] To verify that the four proteins selected as allergens specific for anaphylaxis are specific antigens for anaphylaxis, we evaluated whether each subject's serum reaction occurred. In order to produce the four selected proteins, the genes encoding each protein were synthesized (Bionics Inc.) using the base sequence information published in NCBI. The four genes were each inserted into the p3xFlag-CMV-14 vector, and the genes encoding MHC1 (SEQ ID NO: 1), MHC2 (SEQ ID NO: 2), or hemocyanin (SEQ ID NO: 3) were inserted into the sites of NotI and XbaI, and the gene encoding hemocyanin L1 (SEQ ID NO: 4) was inserted into the sites of HindIII and BamHI to produce each recombinant vector. After confirming the gene sequence of the recombinant vector, the recombinant vector was transfected into human embryonic kidney cell line HEK-293 cells using Lipofectamine 2000 (Invitrogen), and the synthesized protein was purified 40 hours later using Flag beads.

[0062] The verification of allergens specific for anaphylaxis was performed by western blotting. Five sets of the purified proteins were electrophoresed on SDS PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) gels, and then transferred to PVDF (polyvinylidene difluoride) membranes and blocked with 5% BSA (bovine serum albumin) for 1 hour. For each protein, sera from the blank, normal control, acute urticaria (AU) and anaphylaxis (ANA) groups, among which the house dust mite-negative (Anaphylaxis without HDM) and house dust mite-positive (Anaphylaxis with HDM) groups were reacted overnight. After the reaction was completed, the samples were washed three times, and then biotin-conjugated anti-human IgE antibodies and HRP (Horseradish Peroxidase)-conjugated streptavidin were sequentially reacted, or HRP (Horseradish Peroxidase)-conjugated anti-human IgG antibodies were reacted, and the amounts of IgE and IgG were measured using the Chemi-Doc® Imaging System and Clarity® ECL Solutions (Bio-Rad).

[0063] As shown in Figures 4 and 5, it was confirmed that specific IgE to MHC1 (Myosin Heavy Chain Type 1), hemocyanin, and hemocyanin L1 was present only in the anaphylaxis group, regardless of the presence or absence of house dust mites. The above results demonstrate that IgE that specifically binds to MHC1 (Myosin Heavy Chain Type 1), hemocyanin, or hemocyanin L1 is a specific IgE that can diagnose anaphylaxis, and that anaphylaxis to shrimp can be diagnosed based on the presence or absence of IgE that specifically binds to MHC1 (Myosin Heavy Chain Type 1), hemocyanin, or hemocyanin L1 in the patient's blood.

[0064]

[0065] Example 3. Identification of antigenic determinants (epitopes) in allergens

[0066] To analyze the epitope that binds to IgE in allergens that can diagnose anaphylaxis to shrimp, MHC1 (Myosin Heavy Chain Type 1) and MHC2 (Myosin Heavy Chain Type 2) proteins were fragmented into N-terminal fragment (N), middle fragment (M), and C-terminal fragment (C) centered on the functional domain as shown in Figure 6. A website-based domain analysis program was used through sequence homology analysis, and both MHC1 and MHC2 were predicted to be myosin motors up to approximately 800 amino acids, and the residues after 800 were divided into two fragments. Specifically, in MHC1 consisting of an amino acid sequence represented by SEQ ID NO: 5 (1913 amino acids), the N-terminal fragment (N) was designed as an amino acid sequence from the 1st to the 800th position from the N-terminus, the middle fragment (M) was designed as an amino acid sequence from the 750th to the 1500th position from the N-terminus, and the C-terminal fragment (C) was designed as an amino acid sequence from the 1201st to the 1913th position from the N-terminus. In MHC2 consisting of an amino acid sequence represented by SEQ ID NO: 6 (1909 amino acids), the N-terminal fragment (N) was designed as an amino acid sequence from the 1st to the 700th position from the N-terminus, the middle fragment (M) was designed as an amino acid sequence from the 650th to the 1400th position from the N-terminus, and the C-terminal fragment (C) was designed as an amino acid sequence from the 1300th to the 1909th position from the N-terminus.

[0067] The genes encoding each fragment were synthesized and inserted into the NotI and XbaI sites of the p3xFlag-CMV-14 vector to produce recombinant vectors, respectively. The recombinant vectors were transfected into human embryonic kidney cell lines, HEK-293 cells, using Lipofectamine 2000 (Invitrogen), and the synthesized proteins were purified 40 hours later using Flag beads. As shown in Figure 7, the production of each protein fragment was confirmed using Flag antibody.

[0068] For each protein fragment, the sera from the blank, normal control, acute urticaria (AU) and anaphylaxis (ANA) groups, among which the sera were negative for house dust mites (Anaphylaxis without HDM) and positive for house dust mites (Anaphylaxis with HDM), were reacted overnight. The amount of IgE was analyzed in the same manner as in Example 2.

[0069] As shown in Fig. 8, IgE was detected only in the anaphylaxis group, and IgE specifically binding to MHC1 (Myosin Heavy Chain Type 1) and MHC2 (Myosin Heavy Chain Type 2) was detected only in the middle fragment (M) and C-terminal fragment (C). The above results demonstrate that the epitope binding to IgE specific for anaphylaxis exists in the middle fragment (M) and C-terminal fragment (C) positions of both MHC1 (Myosin Heavy Chain Type 1) and MHC2 (Myosin Heavy Chain Type 2).

[0070] In order to more accurately verify the antigenic determinant region, the portions corresponding to the middle fragment (M) and the C-terminal fragment (C) of the MHC1 and MHC2 proteins were fragmented into the M1 fragment, the M2 fragment, and the M3 fragment, as shown in Figure 9. Specifically, in MHC1, which consists of the amino acid sequence (1913 amino acids) represented by sequence number 5, the M1 fragment was designed as the 801st to 1042nd amino acid sequence from the N-terminus, the M2 fragment was designed as the 1043rd to 1549th amino acid sequence from the N-terminus, and the M3 fragment was designed as the 1546th to 1913th amino acid sequence from the N-terminus. In MHC2, which is composed of an amino acid sequence (1909 amino acids) represented by sequence number 6, the M1 fragment was designed with an amino acid sequence from the 701st to the 1094th position from the N-terminus, the M2 fragment was designed with an amino acid sequence from the 1095th to the 1401st position from the N-terminus, and the M3 fragment was designed with an amino acid sequence from the 1400th to the 1909th position from the N-terminus.

[0071] The genes encoding each fragment were synthesized and inserted into the NotI and XbaI sites of the p3xFlag-CMV-14 vector to produce recombinant vectors, respectively. The recombinant vectors were transfected into human embryonic kidney cell lines, HEK-293 cells, using Lipofectamine 2000 (Invitrogen), and the synthesized proteins were purified 40 hours later using Flag beads. As shown in Fig. 10, the production of each protein fragment was confirmed using Flag antibody.

[0072] For each protein fragment, the sera from the blank, normal control, acute urticaria (AU) and anaphylaxis (ANA) groups, among which the sera were negative for house dust mites (Anaphylaxis without HDM) and positive for house dust mites (Anaphylaxis with HDM), were reacted overnight. The amount of IgE was analyzed in the same manner as in Example 2.

[0073] As shown in Figure 11, IgE was detected only in the anaphylaxis group, and both IgEs that specifically bind to MHC1 (Myosin Heavy Chain Type 1) and MHC2 (Myosin Heavy Chain Type 2) were found to have high levels of IgE detected in the M1 fragment.

[0074] Through the above results, it is proven that the protein region consisting of the 801st to 1042nd amino acid sequence from the N-terminus in MHC1 consisting of the amino acid sequence represented by sequence number 5 (1913 amino acids) is an antigenic determining site that binds to IgE specific for anaphylaxis, and that the protein region consisting of the 701st to 1094th amino acid sequence from the N-terminus in MHC2 consisting of the amino acid sequence represented by sequence number 6 (1909 amino acids) is an antigenic determining site that binds to IgE specific for anaphylaxis.

[0075] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. In other words, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A biomarker composition for diagnosing anaphylaxis in shrimp, comprising as an active ingredient at least one selected from the group consisting of IgE (immunoglobulin E) specifically binding to MHC1 (Myosin Heavy Chain Type 1), IgE specifically binding to MHC2 (Myosin Heavy Chain Type 2), IgE specifically binding to hemocyanin, and IgE specifically binding to hemocyanin L1.

2. A biomarker composition for diagnosing anaphylaxis in shrimp, characterized in that in paragraph 1, the MHC1 (Myosin Heavy Chain Type 1) consists of an amino acid sequence of sequence number 5, the MHC2 (Myosin Heavy Chain Type 2) consists of an amino acid sequence of sequence number 6, the hemocyanin consists of an amino acid sequence of sequence number 7, and the hemocyanin L1 consists of an amino acid sequence of sequence number 8.

3. A composition for diagnosing anaphylaxis in shrimp, comprising as an active ingredient at least one peptide selected from the group consisting of peptides composed of MHC1 (Myosin Heavy Chain Type 1), MHC2 (Myosin Heavy Chain Type 2), hemocyanin, hemocyanin L1, and epitopes thereof.

4. A composition for diagnosing anaphylaxis in shrimp, characterized in that in paragraph 3, the MHC1 (Myosin Heavy Chain Type 1) consists of an amino acid sequence of sequence number 5, the MHC2 (Myosin Heavy Chain Type 2) consists of an amino acid sequence of sequence number 6, the hemocyanin consists of an amino acid sequence of sequence number 7, and the hemocyanin L1 consists of an amino acid sequence of sequence number 8.

5. A composition for diagnosing anaphylaxis in shrimp, characterized in that in the third paragraph, the epitope is an epitope of MHC1 (Myosin Heavy Chain Type 1) or an epitope of MHC2 (Myosin Heavy Chain Type 2).

6. A composition for diagnosing anaphylaxis in shrimp, characterized in that in paragraph 5, the epitope of MHC1 (Myosin Heavy Chain Type 1) is a protein region consisting of the 750th to 1500th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, a protein region consisting of the 1201st to 1913th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, a protein region consisting of the 801st to 1042nd amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, a protein region consisting of the 1043rd to 1549th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, or a protein region consisting of the 1546th to 1913th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO:

5.

7. A composition for diagnosing anaphylaxis in shrimp, characterized in that in paragraph 5, the epitope of MHC2 (Myosin Heavy Chain Type 2) is a protein region consisting of the 650th to 1400th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, a protein region consisting of the 1300th to 1909th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, a protein region consisting of the 701st to 1094th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, a protein region consisting of the 1095th to 1401st amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, or a protein region consisting of the 1400th to 1909th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO:

6.

8. A kit for diagnosing anaphylaxis, comprising at least one peptide selected from the group consisting of peptides composed of MHC1 (Myosin Heavy Chain Type 1), MHC2 (Myosin Heavy Chain Type 2), hemocyanin, hemocyanin L1, and epitopes thereof.

9. A kit according to claim 8, characterized in that the kit is a kit for immunoassay.

10. A kit according to paragraph 8, characterized in that the kit is for Koreans.

11. A method for providing information for diagnosing anaphylaxis to shrimp, comprising a step of detecting IgE (immunoglobulin E) that binds to at least one peptide selected from the group consisting of peptides consisting of MHC1 (Myosin Heavy Chain Type 1), MHC2 (Myosin Heavy Chain Type 2), hemocyanin, hemocyanin L1, and epitopes thereof, in a biological sample isolated from a subject.

12. A method for providing information for diagnosing anaphylaxis in shrimp, characterized in that in paragraph 11, the biological sample is at least one selected from the group consisting of blood, plasma, serum, urine, mucus, saliva, tears, sputum, spinal fluid, lymph, respiratory fluid, intestinal fluid, and amniotic fluid.

13. A method for providing information for diagnosing anaphylaxis in shrimp, characterized in that in paragraph 11, the MHC1 (Myosin Heavy Chain Type 1) consists of an amino acid sequence of sequence number 5, the MHC2 (Myosin Heavy Chain Type 2) consists of an amino acid sequence of sequence number 6, the hemocyanin consists of an amino acid sequence of sequence number 7, and the hemocyanin L1 consists of an amino acid sequence of sequence number 8.

14. A method for providing information for diagnosing anaphylaxis in shrimp, characterized in that in paragraph 11, the epitope is an epitope of MHC1 (Myosin Heavy Chain Type 1) or an epitope of MHC2 (Myosin Heavy Chain Type 2).

15. A method for providing information for diagnosing anaphylaxis in shrimp, characterized in that in claim 14, the epitope of MHC1 (Myosin Heavy Chain Type 1) is a protein region consisting of the 750th to 1500th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, a protein region consisting of the 1201st to 1913th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, a protein region consisting of the 801st to 1042nd amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, a protein region consisting of the 1043rd to 1549th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 5, or a protein region consisting of the 1546th to 1913th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO:

5.

16. A method for providing information for diagnosing anaphylaxis in shrimp, characterized in that in paragraph 14, the epitope of MHC2 (Myosin Heavy Chain Type 2) is a protein region consisting of the 650th to 1400th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, a protein region consisting of the 1300th to 1909th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, a protein region consisting of the 701st to 1094th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, a protein region consisting of the 1095th to 1401st amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO: 6, or a protein region consisting of the 1400th to 1909th amino acid sequence from the N-terminus of the amino acid sequence represented by SEQ ID NO:

6.

17. A method for providing information for diagnosing anaphylaxis in shrimp, characterized in that the method is for Koreans in Article 11.

Citation Information

Patent Citations

  • Preparation method of shrimp allergen mixture

    CN115980335A

  • Ritical temperature piezo-resistive composites comprising paraffin wax and pressure sensor comprising the same

    KR102201847B1

  • Materials and methods for diagnosing and treating shellfish allergy

    US20150153358A1